IGLL5 and plasma cell myeloma: IGLL5 was also demonstrated to be frequently mutated in B-cell malignancies, such as Hodgkin’s lymphoma (22), diffuse large B-cell lymphoma (DLBCL) (23), multiple myeloma (MM) (24), and CLL with translocations involving IGH (25).